Sionna Therapeutics, Inc. (SION:NASDAQ) closed at $3.33 on November 13, 2026, down 2.92% on the day. The stock trades 93.9% below its 52-week high of $54.97 and 4.4% above its 52-week low of $3.19. Over the past year, it lost 91.7%. Sionna Therapeutics, Inc. is part of the Health Care sector.
In 251 trading sessions since November 13, 2025, SION closed higher on 140 days (56%). Its best day was August 12, 2026 (+22.55%) and its worst was September 18, 2026 (-16.99%). The stock moved 10% or more in a single session 18 times.
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the treatment paradigm for cystic fibrosis (CF) patients. The company focuses on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. Their goal is to deliver differentiated medicines that can restore CFTR function as close to normal as possible by directly stabilizing CFTR's nucleotide-binding domain 1 (NBD1). Sionna is currently conducting Phase 1 trials for two highly potent NBD1 stabilizers and developing a portfolio of complementary CFTR modulators designed to work synergistically with their NBD1 stabilizers to improve CFTR function, as observed in preclinical models.
Find more stocks like SION with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.